Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Clint Doiron

Interventional Cardiology Knoxville, TN Medical Doctor

NPI 1972593663 CMS profile 225062

10800 Parkside Dr Ste 331, Ste 331, Knoxville, TN 37934

Open in the dashboard

General payments

$8,485

431 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Clint Doiron of Knoxville, TN is reported in the CMS Open Payments database as having received $8,485 across 431 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,619 68
2024 General $1,640 84
2023 General $1,527 76
2022 General $774 44
2021 General $1,202 66
2020 General $801 38
2019 General $921 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Clint Doiron
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Clint Doiron were reported at $1,619. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Clint Doiron Interventional Cardiology median Middle half National median
2019 $921 $1,097 $329–$3,048 $163
2020 $801 $473 $161–$1,480 $114
2021 $1,202 $677 $233–$1,827 $132
2022 $774 $978 $333–$2,724 $149
2023 $1,527 $1,136 $382–$2,986 $160
2024 $1,640 $1,181 $395–$3,326 $164
2025 $1,619 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,486 99 payments
  2. Amgen Inc. $917 48 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $884 43 payments
  4. Abbott Laboratories $797 23 payments
  5. Shockwave Medical, Inc $578 42 payments
  6. AstraZeneca Pharmaceuticals LP $549 31 payments
  7. Pfizer Inc. $400 23 payments
  8. HeartFlow, Inc. $285 5 payments
  9. Abiomed $252 2 payments
  10. E.R. Squibb & Sons, L.L.C. $241 13 payments
  11. Other $2,096 102 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,439 428 payments
  2. Education $46 3 payments
Products named General payments · program years 2019–2025
  1. LifeVest $884 43 payments
  2. Repatha $835 44 payments
  3. LEQVIO $807 51 payments
  4. ENTRESTO $462 31 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $419 34 payments
  6. FARXIGA $344 19 payments
  7. ELIQUIS $332 19 payments
  8. CARDIOMEMS $295 2 payments
  9. FFRct $285 5 payments
  10. Impella $252 2 payments
  11. Other $4,279 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 64 drugs

Part D claims

11,155

Median for Cardiology: 2,533

Drug cost

$1,942,412

Median for Cardiology: $485,213

Branded share of claims

33.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 704 $657,475
Repatha Sureclick Evolocumab Brand 441 $385,180
Entresto Sacubitril/Valsartan Brand 315 $272,695
Farxiga Dapagliflozin Propanediol Brand 199 $160,769
Xarelto Rivaroxaban Brand 103 $100,256
Brilinta Ticagrelor Brand 112 $75,109
Jardiance Empagliflozin Brand 72 $73,274
Multaq Dronedarone Hcl Brand 55 $40,520
Praluent Pen Alirocumab Brand 23 $24,813
Prasugrel Hcl Generic 247 $20,907

The 10 drugs with the highest cost, of 64 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$137,761

Medicare's payments for the services billed

Medicare patients

1,016

Average age 76

Services billed

2,436

509 women, 507 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 56%
Arthritis 55%
Atrial fibrillation 39%
Diabetes 37%
Chronic kidney disease 35%
Heart failure 30%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $209
$209 441 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $204
$204 — —
ELIQUIS
  • PFIZER INC. $72
  • E.R. Squibb & Sons, L.L.C. $17
$89 704 —
Ozempic
  • Novo Nordisk Inc $56
$56 15 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $52
$52 199 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

431 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record